Scott Vafai

Scott Vafai is executive director, translational medicine at Verve Therapeutics, where he provides clinical and translational leadership to drive the design and interpretation of Verve’s clinical programs. Prior to joining Verve, Dr. Vafai was senior director of translational medicine and clinical pharmacology at Sanofi with a focus on gene therapy. During his time at Sanofi, he was responsible for advancing an AAV gene therapy program from research into a first-in-human study. Prior to Sanofi, Dr. Vafai directed an industry-funded mitochondrial therapeutics discovery group at the Broad Institute. He is a co-founder of Metavention, a clinical stage company developing hepatic denervation for the treatment of type 2 diabetes. Dr. Vafai completed his residency in internal medicine at Brigham and Women’s Hospital and fellowship in endocrinology at Massachusetts General Hospital. His post-doctoral training was focused on mitochondrial biology with Dr. Vamsi Mootha at Massachusetts General Hospital and the Broad Institute. He holds an M.D. from the Harvard-MIT Health Sciences and Technology Program and an A.B. in molecular biology from Princeton University.